Ontology type: schema:ScholarlyArticle Open Access: True
2019-12
AUTHORSLana McClements, Stephanie Annett, Anita Yakkundi, Martin O'Rourke, Andrea Valentine, Nermeen Moustafa, Abdelrahim Alqudah, Bruno M Simões, Fiona Furlong, Amy Short, Stuart A McIntosh, Helen O McCarthy, Robert B Clarke, Tracy Robson
ABSTRACTBACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease. METHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test. RESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n ≥ 3, p < 0.05) and invasion (n ≥ 3, p < 0.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p < 0.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n ≥ 3, p < 0.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p < 0.05) or 21 days (p < 0.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4. CONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant CSCs; both areas of unmet clinical need. More... »
PAGES351
http://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0
DOIhttp://dx.doi.org/10.1186/s12885-019-5500-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1113377817
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30975104
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "University of Technology Sydney",
"id": "https://www.grid.ac/institutes/grid.117476.2",
"name": [
"Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.",
"School of Pharmacy, Queen's University Belfast, Belfast, UK.",
"The School of Life Sciences, University of Technology Sydney, Sydney, Australia."
],
"type": "Organization"
},
"familyName": "McClements",
"givenName": "Lana",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal College of Surgeons in Ireland",
"id": "https://www.grid.ac/institutes/grid.4912.e",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK.",
"Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland."
],
"type": "Organization"
},
"familyName": "Annett",
"givenName": "Stephanie",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK."
],
"type": "Organization"
},
"familyName": "Yakkundi",
"givenName": "Anita",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK.",
"Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK."
],
"type": "Organization"
},
"familyName": "O'Rourke",
"givenName": "Martin",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK.",
"Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK."
],
"type": "Organization"
},
"familyName": "Valentine",
"givenName": "Andrea",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK."
],
"type": "Organization"
},
"familyName": "Moustafa",
"givenName": "Nermeen",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hashemite University",
"id": "https://www.grid.ac/institutes/grid.33801.39",
"name": [
"Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.",
"School of Pharmacy, Hashemite University, Amman, Jordan."
],
"type": "Organization"
},
"familyName": "Alqudah",
"givenName": "Abdelrahim",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Manchester",
"id": "https://www.grid.ac/institutes/grid.5379.8",
"name": [
"Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK."
],
"type": "Organization"
},
"familyName": "Sim\u00f5es",
"givenName": "Bruno M",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK."
],
"type": "Organization"
},
"familyName": "Furlong",
"givenName": "Fiona",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK."
],
"type": "Organization"
},
"familyName": "Short",
"givenName": "Amy",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Belfast City Hospital",
"id": "https://www.grid.ac/institutes/grid.412914.b",
"name": [
"Centre for Cancer Research and Cell Biology, Queen's University Belfast and Breast Surgery Department, Belfast City Hospital, Belfast, UK."
],
"type": "Organization"
},
"familyName": "McIntosh",
"givenName": "Stuart A",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University Belfast",
"id": "https://www.grid.ac/institutes/grid.4777.3",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK."
],
"type": "Organization"
},
"familyName": "McCarthy",
"givenName": "Helen O",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Manchester",
"id": "https://www.grid.ac/institutes/grid.5379.8",
"name": [
"Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK."
],
"type": "Organization"
},
"familyName": "Clarke",
"givenName": "Robert B",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal College of Surgeons in Ireland",
"id": "https://www.grid.ac/institutes/grid.4912.e",
"name": [
"School of Pharmacy, Queen's University Belfast, Belfast, UK. tracyrobson@rcsi.ie.",
"Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland. tracyrobson@rcsi.ie."
],
"type": "Organization"
},
"familyName": "Robson",
"givenName": "Tracy",
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/nature10983",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014607335",
"https://doi.org/10.1038/nature10983"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1371/journal.pone.0055075",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022426445"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.18632/oncotarget.3410",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049700121"
],
"type": "CreativeWork"
}
],
"datePublished": "2019-12",
"datePublishedReg": "2019-12-01",
"description": "BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease.\nMETHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer\u00a0models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test.\nRESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n\u2009\u2265\u20093, p\u2009<\u20090.05) and invasion (n\u2009\u2265\u20093, p\u2009<\u20090.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p\u2009<\u20090.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n\u2009\u2265\u20093, p\u2009<\u20090.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p\u2009<\u20090.05) or 21\u2009days (p\u2009<\u20090.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4.\nCONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant\u00a0CSCs; both areas of unmet clinical need.",
"genre": "research_article",
"id": "sg:pub.10.1186/s12885-019-5500-0",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1024632",
"issn": [
"1471-2407"
],
"name": "BMC Cancer",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "19"
}
],
"name": "FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.",
"pagination": "351",
"productId": [
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12885-019-5500-0"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1113377817"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"100967800"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30975104"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12885-019-5500-0",
"https://app.dimensions.ai/details/publication/pub.1113377817"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-16T06:25",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000003.jsonl",
"type": "ScholarlyArticle",
"url": "https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5500-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'
This table displays all metadata directly associated to this object as RDF triples.
173 TRIPLES
21 PREDICATES
31 URIs
20 LITERALS
8 BLANK NODES